thalidomide has been researched along with n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, Y; Matsushima, T; Muta, K; Nawata, H; Nishimura, J; Zhang, M | 1 |
| Brady, H; Chan, K; Corral, LG; De Parseval, LM; Ferguson, GD; Jensen-Pergakes, K; Jhaveri, U; Morris, CL; Richard, N; Verhelle, D; Wilkey, C; Xie, W | 1 |
2 other study(ies) available for thalidomide and n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
| Article | Year |
|---|---|
Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dexamethasone; Dose-Response Relationship, Drug; Fas Ligand Protein; Genes, bcl-2; Humans; Membrane Glycoproteins; Membrane Proteins; Multiple Myeloma; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Sulfonamides; Thalidomide | 2005 |
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Gene Expression; Humans; Immunologic Factors; Immunoprecipitation; Lipopolysaccharides; Membrane Proteins; Monocytes; Nitrobenzenes; Prostaglandins; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Thalidomide; Transcription, Genetic | 2007 |